Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Raytheon wins $42.5 million in Navy F/A-18 spare parts deals
• Citigroup set to join top banks in Anthropic IPO - Bloomberg